https://repositorio.ufba.br/handle/ri/6946
Tipo: | Artigo de Periódico |
Título: | Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
Título(s) alternativo(s): | Brazilian Journal of Infectious Diseases |
Autor(es): | Parise, E. Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. |
Autor(es): | Parise, E. Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. |
Abstract: | Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed 57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological response when retreated with peginterferon alfa-2a (40KD) and ribavirin. The safety profile is similar to that of naive patients. |
Palavras-chave: | Peginterferon alfa Ribavirin Hepatitis C Safety Efficacy |
Editora / Evento / Instituição: | The Brazilian Journal of Infectious Diseases and Contexto Publishing |
URI: | http://www.repositorio.ufba.br/ri/handle/ri/6946 |
Data do documento: | Fev-2006 |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Parise, E..pdf | 563,94 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.